FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584143259> ?p ?o ?g. }

• W2584143259 abstract "Abstract Abstract 4437 In order to describe the different treatments and factors involved in the first major molecular response (MMR) occurence in chronic phase CML, its maintenance, and its conversion to complete molecular response (CMR), we analyzed 211 CML patients [124 males and 87 females; median age: 50 years (17–81)] in first chronic phase who received tyrosine-kinase inhibitors (TKI) followed at our institution between 2001 and 2011. Among 196 patients evaluated for Sokal score, 79 (40%) were low, 82 (42%) were intermediate and 35 (18%) were high. According to hasford score (153 evaluated), 46% were low, 46% intermediate and 8% were high. First MMR was obtained in: 61% of patients after first line treatment [Imatinib, n=102; Imatinib+Peg-interferon, n=11; Dasatinib, n=10; Nilotinib, n=6]; 26% after second line [Imatinib, n=32; Dasatinib, n=11; Nilotinib, n=12] and 13% beyond second line [Imatinib, n=14; Dasatinib, n=7; Nilotinib, n=6]. The median time of MMR obtention was 15 months (2.5–94) after Imatinib, 6.4 months (3–24) after Imatinib+Peg-interferon, and it was significantly shorter after both Dasatinib [HR=2.6 (1.7–3.9), p<0.001] and Nilotinib [HR=3 (1.8–5), p<0.001] with 6 months (3–23) and 5 months (3–56) respectively no matter the treatment line number was. Sokal score was an independent significant factor that impacted MMR obtention delay, with a median time of 9 months (2.5–98) for low score, 13 months (3–78) for intermediate [HR=0.7 (0.5–0.9), p=0.03] and 12 months (3–94) for high score [HR=0.7 (0.5–1.02), p=0.05]. Patients who converted to CMR were: 50 (34%) under Imatinib after a median time of 25 months (3–97); 7 (64%) under Imatinib+Peg-interferon after a median time of 8 months (3–15); 10 (42%) under Nilotinib after 25 months (13–32) and the only significant faster treatment was Dasatinib [n=13 (46%)] after a median time of 11 months (3–52) [HR=2.1 (1.1–4.2), p=0.02]; according to Sokal score, low (n=41, 52%) and intermediate (n=27, 33%), while patients with high score (n=11, 31%) were significantly slower [HR=0.53 (0.25–1), p<0.001]. The current rate of CMR at 5 years was not statistically different between the treatments [Imatinib (36%), Imatinib+Peg-interferon (40%), Nilotinib (43%), Dasatinib (56.5%)] nor according to sokal score [Low (49%), intermediate (43%) and high (40%)]. Treatment was discontinued in 42 patients who had 5 years failure-free survival of 56% (43–73) while patients under Dasatinib, Imatinib+Peg-interferon, Imatinib, and Nilotinib had 70.5% (50–99), 79% (56–100), 84% (77–91) and 93% (84–100) respectively. In Conclusion, second generation TKI used at 1st, 2nd line or beyond, showed an independent significant faster time to MMR, as well as patients with low sokal score. Conversion to CMR was significantly faster only in Dasatinib patients and slower in patients with intermediate and high sokalscore. Treatment discontinuation did not have a benefit in terms of FFS while patients on TKI therapy seem to have better result. Disclosures: Nicolini: Novartis, Bristol Myers-Squibb, Pfizer, ARIAD, and Teva: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2584143259 created "2017-02-10" @default.
• W2584143259 creator A5005285747 @default.
• W2584143259 creator A5026906275 @default.
• W2584143259 creator A5034129814 @default.
• W2584143259 creator A5038427683 @default.
• W2584143259 creator A5045283637 @default.
• W2584143259 creator A5045974510 @default.
• W2584143259 creator A5062694494 @default.
• W2584143259 creator A5072027146 @default.
• W2584143259 creator A5077014294 @default.
• W2584143259 creator A5077614586 @default.
• W2584143259 creator A5078817313 @default.
• W2584143259 creator A5086317399 @default.
• W2584143259 creator A5086596662 @default.
• W2584143259 date "2012-11-16" @default.
• W2584143259 modified "2023-10-13" @default.
• W2584143259 title "MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free Survival" @default.
• W2584143259 doi "https://doi.org/10.1182/blood.v120.21.4437.4437" @default.
• W2584143259 hasPublicationYear "2012" @default.
• W2584143259 type Work @default.
• W2584143259 sameAs 2584143259 @default.
• W2584143259 citedByCount "0" @default.
• W2584143259 crossrefType "journal-article" @default.
• W2584143259 hasAuthorship W2584143259A5005285747 @default.
• W2584143259 hasAuthorship W2584143259A5026906275 @default.
• W2584143259 hasAuthorship W2584143259A5034129814 @default.
• W2584143259 hasAuthorship W2584143259A5038427683 @default.
• W2584143259 hasAuthorship W2584143259A5045283637 @default.
• W2584143259 hasAuthorship W2584143259A5045974510 @default.
• W2584143259 hasAuthorship W2584143259A5062694494 @default.
• W2584143259 hasAuthorship W2584143259A5072027146 @default.
• W2584143259 hasAuthorship W2584143259A5077014294 @default.
• W2584143259 hasAuthorship W2584143259A5077614586 @default.
• W2584143259 hasAuthorship W2584143259A5078817313 @default.
• W2584143259 hasAuthorship W2584143259A5086317399 @default.
• W2584143259 hasAuthorship W2584143259A5086596662 @default.
• W2584143259 hasConcept C121608353 @default.
• W2584143259 hasConcept C126322002 @default.
• W2584143259 hasConcept C143998085 @default.
• W2584143259 hasConcept C170493617 @default.
• W2584143259 hasConcept C2777413986 @default.
• W2584143259 hasConcept C2777583451 @default.
• W2584143259 hasConcept C2778208673 @default.
• W2584143259 hasConcept C2778729363 @default.
• W2584143259 hasConcept C2778820342 @default.
• W2584143259 hasConcept C2779536868 @default.
• W2584143259 hasConcept C2993493390 @default.
• W2584143259 hasConcept C3019892230 @default.
• W2584143259 hasConcept C42362537 @default.
• W2584143259 hasConcept C71924100 @default.
• W2584143259 hasConceptScore W2584143259C121608353 @default.
• W2584143259 hasConceptScore W2584143259C126322002 @default.
• W2584143259 hasConceptScore W2584143259C143998085 @default.
• W2584143259 hasConceptScore W2584143259C170493617 @default.
• W2584143259 hasConceptScore W2584143259C2777413986 @default.
• W2584143259 hasConceptScore W2584143259C2777583451 @default.
• W2584143259 hasConceptScore W2584143259C2778208673 @default.
• W2584143259 hasConceptScore W2584143259C2778729363 @default.
• W2584143259 hasConceptScore W2584143259C2778820342 @default.
• W2584143259 hasConceptScore W2584143259C2779536868 @default.
• W2584143259 hasConceptScore W2584143259C2993493390 @default.
• W2584143259 hasConceptScore W2584143259C3019892230 @default.
• W2584143259 hasConceptScore W2584143259C42362537 @default.
• W2584143259 hasConceptScore W2584143259C71924100 @default.
• W2584143259 hasLocation W25841432591 @default.
• W2584143259 hasOpenAccess W2584143259 @default.
• W2584143259 hasPrimaryLocation W25841432591 @default.
• W2584143259 hasRelatedWork W1964358866 @default.
• W2584143259 hasRelatedWork W1965429870 @default.
• W2584143259 hasRelatedWork W1967550842 @default.
• W2584143259 hasRelatedWork W2057206328 @default.
• W2584143259 hasRelatedWork W2072834954 @default.
• W2584143259 hasRelatedWork W2111285600 @default.
• W2584143259 hasRelatedWork W2127133818 @default.
• W2584143259 hasRelatedWork W2230151041 @default.
• W2584143259 hasRelatedWork W2378200925 @default.
• W2584143259 hasRelatedWork W2406641958 @default.
• W2584143259 hasRelatedWork W2467870347 @default.
• W2584143259 hasRelatedWork W2766439257 @default.
• W2584143259 hasRelatedWork W2789454304 @default.
• W2584143259 hasRelatedWork W2884382178 @default.
• W2584143259 hasRelatedWork W2980354645 @default.
• W2584143259 hasRelatedWork W2985522202 @default.
• W2584143259 hasRelatedWork W2990542447 @default.
• W2584143259 hasRelatedWork W3106044074 @default.
• W2584143259 hasRelatedWork W3135877072 @default.
• W2584143259 hasRelatedWork W3197084562 @default.
• W2584143259 isParatext "false" @default.
• W2584143259 isRetracted "false" @default.
• W2584143259 magId "2584143259" @default.
• W2584143259 workType "article" @default.